Kirsten Schaffer, Jaythoon Hassan, Anthony Staines, Suzie Coughlan, Paul Holder, Gráinne Tuite, Aiden P. McCormick, Oscar Traynor, William W. Hall, Jeff Connell – 11 August 2011 – Epstein‐Barr virus (EBV)–associated posttransplant lymphoproliferative disorder (PTLD) is a life‐threatening complication after adult orthotopic liver transplantation (AOLT).

Amina Huda, Robert Newcomer, Charlene Harrington, Mary G. Blegen, Emmet B. Keeffe – 11 August 2011 – The goal of liver transplantation (LT) is to maximize the length and quality of a patient's life and facilitate his or her return to full productivity. The aims of this study were (1) to use the United Network for Organ Sharing (UNOS) data set to determine the proportions of recipients who were employed and unemployed within 24 months after LT between 2002 and 2008 and (2) to examine the factors associated with a return to employment.

Luca Valenti, Silvia Fargion – 11 August 2011

Mariëlle Verweij, Tessa M. van Ginhoven, James R. Mitchell, Wim Sluiter, Sandra van den Engel, Henk P. Roest, Elham Torabi, Jan N. M. IJzermans, Jan H. J. Hoeijmakers, Ron W. F. de Bruin – 11 August 2011

Kenneth A. Andreoni, Tomasz Kozlowski – 11 August 2011

Thomas D. Boyer, Arun J. Sanyal, Guadalupe Garcia‐Tsao, Frederick Regenstein, Lorenzo Rossaro, Beate Appenrodt, Veit Gülberg, Samuel Sigal, Alice S. Bexon, Peter Teuber, the Terlipressin Study Group – 11 August 2011 – The development of hepatorenal syndrome type 1 (HRS1) is associated with a poor prognosis. Liver transplantation improves this prognosis, but the degree of the improvement is unclear. Most patients receive vasoconstrictors such as terlipressin before transplantation, and this may affect the posttransplant outcomes.

Alessandro Cucchetti, Matteo Cescon, Eleonora Bigonzi, Fabio Piscaglia, Rita Golfieri, Giorgio Ercolani, Maria Cristina Morelli, Matteo Ravaioli, Antonio Daniele Pinna – 11 August 2011 – The allocation rules for patients with hepatocellular carcinoma (HCC) who are awaiting liver transplantation (LT) are a difficult issue and are continually evolving. To reduce tumor progression or down‐stage advanced disease, most transplant centers have adopted the practice of treating HCC candidates with resection or locoregional therapies.

David Goldberg, Benjamin French, Arwin Thomasson, K. Rajender Reddy, Scott D. Halpern – 11 August 2011 – The ability of the Model for End‐Stage Liver Disease (MELD) score to capture the urgency of transplantation may not be generalizable to patients with primary sclerosing cholangitis (PSC) because these patients face unique risks of death or removal from the liver transplant waitlist due to disease‐specific complications (eg, repeated bouts of bacterial cholangitis and cholangiocarcinoma).

Kenneth Washburn – 11 August 2011

Norman M. Kneteman, Sonal Asthana, Jamie Lewis, Chelcey Dibben, Donna Douglas, Mahra Nourbakhsh, Lorne J. Tyrrell, Garry Lund – 11 August 2011 – Cyclosporine A (CSA) has potent effects against hepatitis C virus (HCV) in vitro, but its clinical efficacy after liver transplantation (LT) is uncertain. We evaluated the impact of CSA and tacrolimus (TAC) with or without concomitant interferon (IFN) therapy on serum HCV titers in a chimeric mouse model of HCV infection. Six groups of HCV‐infected mice received only the vehicle, IFN, CSA, CSA and IFN, TAC, or TAC and IFN for 4 weeks.